SereNeuro Therapeutics

CompanyUnited States

SereNeuro Therapeutics develops one asset, preclinical (SN101 in chronic joint pain). Mostly cell therapy; based in the United States.

1
Asset
Furthest stage
Preclinical
0
Trials
0
Signals

Pipeline

1
  • SN101

    iPSC-derived non-opioid cell therapy for chronic joint pain

    Preclinical, Cell therapy, chronic joint pain

Full company profiles: pipeline, trials, funding and people.

See Pro

Intelligence